Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Estrogen/progesterone - Transdermal Delivery Solutions

Next Previous
Drug Profile

Estrogen/progesterone - Transdermal Delivery Solutions

Alternative Names: Estrogen + Progesterone - Transdermal Delivery Solutions; Estrogen/progesterone spray - Transdermal Delivery Solutions; Estrogen/progesterone TDS®

Latest Information Update: 24 Aug 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Transdermal Delivery Solutions Corp
  • Developer St. Bartholomews Hospital; Transdermal Delivery Solutions Corp
  • Class Gonadal steroid hormones; Hormonal contraceptives; Hormonal replacements
  • Mechanism of Action Estrogen receptor agonists; Progesterone receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Menopausal syndrome

Most Recent Events

  • 24 Aug 2023 Discontinued - Preclinical for Menopausal syndrome in USA (Transdermal) (Transdermal Delivery Solutions Corp pipeline, August 2023)
  • 28 Jul 2018 No recent reports of development identified for preclinical development in Menopausal-syndrome in USA (Transdermal, Spray)
  • 27 May 2016 Estrogen/progesterone transdermal is still in non-clinical development for Menopausal syndrome (Company website - May 2016)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top